logo-top-w
  • HOME
  • ABOUT MORSE
    • About Us
    • The Team
      • Arvind Mani
      • Sherry O’Quinn
      • Brad Alyward
      • Anita Gadhok
      • Sophia Gran-Ruaz
      • Avery Hughes
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
  • SERVICES
    • Our Services
    • Strategic Advice
    • Analyses
    • Advisory Boards
    • Training
    • Reports
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c
logo-top-w
  • HOME
  • ABOUT MORSE
    • About Us
    • The Team
      • Arvind Mani
      • Sherry O’Quinn
      • Brad Alyward
      • Anita Gadhok
      • Sophia Gran-Ruaz
      • Avery Hughes
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
  • SERVICES
    • Our Services
    • Strategic Advice
    • Analyses
    • Advisory Boards
    • Training
    • Reports
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

pCPA Update as of February 28, 2017

March 16, 2017
-
Market Access News
-
Posted by MORSE Team - < 1 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of February 28, 2017.

  • There are currently 33 negotiations underway with one new file – Eylea (aflibercept) was added since the last update on January 31, 2017.
  • There have been 142 joint negotiations completed with 8 files successfully negotiated since the last update of January 31, 2017:
    1. Daklinza (daclatasvir): Used to treat chronic Hepatitis C infection
    2. Epclusa (sofosbuvir/velpatasvir): Used to treat chronic Hepatitis C infection
    3. Harvoni (sofosbuvir/ledipsavir)* (second letter of intent): Used to treat chronic Hepatitis C infection
    4. Plegridy (PegIFN beta-1a): Used to treat relapsing-remitting multiple sclerosis (RRMS)
    5. Sovaldi (sofosbuvir)* (second letter of intent): Used to treat chronic Hepatitis C infection
    6. Sunvepra (asunaprevir): Used to treat chronic Hepatitis C infection
    7. Technivie (ombitasvir/ paritaprevir/ ritonavir): Used for the treatment of Hepatitis C (genotype 4)
    8. Zepatier (elbasvir grazoprevir): Used for the treatment of Hepatitis C (genotype 1, 4)
  • There continues to be 49 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level as of February 28, 2017.
  • There remains 13 negotiations for brand name drug products that have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of February 28, 2017.

Please visit the pCPA website for more information.

 

To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

 

Share
Tags
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
← PREVIOUS POST
Market Access Advisory Board Meetings: Bridging the Gap Between Market Access and Internal Stakeholders
NEXT POST →
Health Canada Guidance Document on the Disclosure of Confidential Business Information – March 10, 2017

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering pharmaceutical market access signals to create reimbursement success.
© 2019 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
pCPA Update as of February 28, 2017
css.php